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Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor 
prognosis. We propose that instead of continuing on bevacizumab, patients should switch to 
treatment with Optune™, a novel antimitotic Tumor-Treating Fields (TTFields) therapy ap-
proved in the United States for newly diagnosed and recurrent GBM. This would reserve 
bevacizumab for subsequent disease progression. In this case series, we describe 8 patients 
with recurrent GBM who had disease progression on bevacizumab, discontinued bevaci-
zumab treatment, and were treated with TTFields therapy alone. After subsequent radio-
graphic or clinical progression, 5 patients were rechallenged with bevacizumab in a ‘pulse 
dose’ fashion, an approach not previously described. Following treatment with TTFields ther-
apy, median overall survival (OS) was 216 days (7.2 months). Median OS from last dose of 
initial bevacizumab was 237 days (7.9 months), twice that of historical controls for bevaci-
zumab failures, and median OS from the first dose of bevacizumab rechallenge was 172 days 
(5.7 months). TTFields therapy was well tolerated, with a mean adherence rate of 74.2% 
(range, 48.2–92.9%). These results support the use of TTFields therapy with pulse dose 
bevacizumab as an option in patients with refractory GBM. © 2016 The Author(s) 
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Glioblastoma (GBM) is the most common primary malignant neoplasm of the central 
nervous system in adults [1], with a median overall survival (OS) of 14.6 months with stand-
ard chemoradiation [2]. Patients with recurrent GBM have limited treatment options [3]. 
Bevacizumab (Avastin®; Genentech, Inc., South San Francisco, Calif., USA), is an anti-VEGF 
recombinant humanized monoclonal antibody approved in the United States as a single 
agent for recurrent GBM [4]. Although radiographic responses are observed on MRI follow-
ing treatment with bevacizumab [5–7], to date, no direct comparison between bevacizumab 
and cytotoxic chemotherapy has been conducted, and it remains unclear if bevacizumab 
improves OS in patients with recurrent GBM [6]. However, while on bevacizumab, patients 
may derive clinical benefits that include decreased cerebral edema, improved neurologic 
symptoms, and decreased corticosteroid use [7]. Once refractory to bevacizumab, patients 
are unlikely to respond to subsequent regimens, whether they contain bevacizumab or not 
[8], and inevitably relapse [9]. Median OS after bevacizumab failure has ranged from approx-
imately 1.1 to 4.5 months regardless of treatment [10, 11]. 
OptuneTM (Novocure Inc., Portsmouth, N.H., USA), previously known as the NovoTTF-
100A System, a portable device delivering low-intensity intermediate-frequency (200 kHz) 
alternating antimitotic tumor-treating fields (TTFields) via noninvasive transducer arrays, is 
approved in the United States to treat adults with newly diagnosed as well as recurrent GBM 
as an alternative to standard medical therapy [3]. A phase 3 study of TTFields therapy versus 
physicians’ choice of chemotherapy in patients with recurrent GBM resulted in a median OS 
of 6.6 months for TTFields therapy alone versus 6.0 months for chemotherapy (HR 0.86; 
95% CI 0.66–1.12; p = 0.27), with more responses and fewer adverse events in the TTFields 
therapy arm [3]. Post-hoc analyses of these data demonstrated that patients with bevaci-
zumab-refractory GBM who were treated with TTFields therapy alone had a median OS of 
6.0 months compared with 3.3 months for chemotherapy alone [11]. 
Rapid tumor regrowth or radiographic tumor-rebound phenomenon has been reported 
after withdrawal of bevacizumab in patients with recurrent high-grade glioma, leading to an 
accelerated clinical decline [10]. For this reason, many physicians are reluctant to discontin-
ue bevacizumab even after bevacizumab failure has been well documented, leading to poten-
tial overtreatment. However, due to the antimitotic mechanism of action of TTFields therapy 
[12], it is possible that patients with bevacizumab-refractory recurrent GBM will benefit 
maximally from TTFields therapy after bevacizumab has been withdrawn and rapid tumor 
proliferation sets in. Bevacizumab treatment can be resumed for subsequent radiographic 
progression or worsening symptoms, due to either further disease progression or other in-
flammatory responses to TTFields-induced cell death. This case series describes the out-
comes for 8 patients with bevacizumab-refractory GBM, who were treated with TTFields 
therapy alone, then with concomitant pulse dose bevacizumab for subsequent radiographic 
progression in 5 patients. 
Methods 
Patients were diagnosed with GBM from August 2011 to May 2013 and ranged in age 
from 35 to 62 years; 5 were male. 
Six of the 8 patients underwent standard treatment for GBM of maximal surgical resec-
tion followed by radiotherapy and temozolomide [2, 9]. Baseline demographics and charac-
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radiation therapy (∼60 Gy) with concurrent temozolomide 75 mg/m2/day; 6 patients re-
ceived from 1 to 10 cycles of high-dose maintenance temozolomide. One patient participated 
in the phase 3 DCVax-L study for newly diagnosed GBM, receiving dendritic cell-based vac-
cine versus placebo. Another participated in the phase 3 EF-14 study testing TTFields thera-
py in newly diagnosed GBM, but was randomized to the control arm and received adjuvant 
temozolomide alone. 
Following their first disease recurrence, the patients received a number of different 
treatments (table 1). Of the 8 patients, 7 had participated in clinical trials for their recurrent 
GBM; 5 had participated in one clinical trial, and 2, in two trials. All received bevacizumab at 
10 mg/kg every 2 weeks in addition to experimental agents where appropriate, which in-
cluded rindopepimut, the anti-EGFRvIII mutation vaccine; dasatinib, a Src tyrosine kinase 
inhibitor; and vorinostat, a histone deacetylase inhibitor. 
Once unequivocal radiographic evidence of bevacizumab-refractory disease progression 
using Response Assessment in Neuro-Oncology criteria was confirmed, bevacizumab was 
discontinued and TTFields therapy was delivered using two pairs of noninvasive insulated 
disposable arrays applied to the shaved scalp [3, 12]. For 7 patients, TTFields therapy was 
administered third-line following disease progression on bevacizumab. One patient had sur-
gery at disease recurrence followed by bevacizumab; therefore, TTFields therapy was ad-
ministered fourth-line. One of the 8 patients received TTFields therapy for disease recur-
rence on a clinical trial. 
Following radiographic progression while on TTFields therapy, 5 patients were rechal-
lenged with bevacizumab 10 mg/kg every 2 weeks. Patients were monitored for radiograph-
ic and clinical progression; TTFields therapy and/or bevacizumab were discontinued at the 
discretion of the treating physicians. 
Survival data were collected between several time points: time from first day of 
TTFields therapy to death, time from last dose of first round of bevacizumab to death, and 
time from first dose of bevacizumab rechallenge until death. Patient deaths were confirmed 
by hospital records, death certificate, and/or obituary notice. 
Case Reports 
Patient narratives for each of the 8 patients are presented below. 
Patient No. 1, a male in his 40s, was diagnosed with a right frontal lobe GBM. He under-
went near gross total resection (GTR) and received concomitant radiation therapy and te-
mozolomide. Molecular testing revealed his tumor was MGMT negative. He subsequently 
declined high-dose maintenance temozolomide and was treated with bevacizumab in a clini-
cal trial. Disease recurrence was detected at month 13, and he subsequently received bevaci-
zumab for 5 months before developing further progression at month 20 after diagnosis. 
TTFields therapy was subsequently started for 4 months before further disease progression 
was documented at month 25 after diagnosis, and the patient died at month 28. His adher-
ence rate is not available, as this patient was lost to follow-up. 
Patient No. 2, a male in his 40s, was diagnosed with right temporal lobe GBM. He un-
derwent GTR and received radiation therapy and temozolomide. His tumor was MGMT nega-
tive and IDH negative. He received only 1 cycle of high-dose maintenance temozolomide due 
to disease progression on MRI. The patient’s tumor recurred at month 5, and he received 
bevacizumab from months 5 to 11. TTFields therapy was initiated at month 13 and contin-
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month 14. The patient was not rechallenged with bevacizumab due to an intracerebral hem-
orrhage, he died at month 14. 
Patient No. 3, a female in her 50s, was diagnosed with right frontal lobe secondary re-
current GBM. She had a 30-year history of a prior low-grade glioma. She underwent near-
GTR and received radiation therapy and temozolomide; however, due to subsequent myelo-
suppression, she did not receive high-dose maintenance temozolomide. Her tumor was IDH1 
positive, EGFR amplification negative, loss of 10q negative, and 1p,19q co-deletion negative. 
She was treated with bevacizumab from months 2 to 9, when disease recurrence was detect-
ed. TTFields therapy was started at month 9, and she was rechallenged with bevacizumab at 
month 11. Her last MRI, at month 13, showed no disease progression. Both TTFields therapy 
and bevacizumab were discontinued at month 14, due to intracerebral hemorrhage resulting 
from a fall. The patient subsequently declined and died 16 months from her GBM diagnosis. 
Her adherence rate to TTFields therapy was 84.0%. 
Patient No. 4, a female in her 60s, was diagnosed with right frontal lobe GBM. Molecular 
testing revealed her tumor to be MGMT positive. She underwent partial resection and re-
ceived concomitant radiation therapy and temozolomide. She was enrolled in the EF-14 
phase clinical trial of temozolomide therapy with and without TTFields therapy for newly 
diagnosed GBM and was randomly assigned to the temozolomide alone arm. At disease pro-
gression at month 5, she was treated with bevacizumab in a clinical trial from months 6 to 
17, when her tumor progressed. TTFields therapy was initiated at month 18, and the pa-
tient’s tumor progressed at month 22, when she was maintained on TTFields therapy and 
rechallenged with bevacizumab. Both treatments were terminated at month 26, and the 
patient died at month 27. Her adherence rate to TTFields therapy was 92.9%. 
Patient No. 5, a male in his 30s, was diagnosed with left frontal lobe secondary GBM. The 
patient did not receive radiation therapy since he had received radiation therapy for a prior 
low-grade glioma 5 years prior to the GBM diagnosis. His tumor tested MGMT negative, 
1p,19q co-deletion negative, EGFR amplification negative, IDH1 positive, and loss of 
P16/CDKN 2A positive. He completed 6 cycles of high-dose maintenance temozolomide, 
which was stopped due to disease progression on MRI. He was then treated with bevaci-
zumab in a clinical trial from months 2 to 10, when his tumor progressed. TTFields was 
started at month 12. Disease progression was documented at month 14, and he was rechal-
lenged with bevacizumab. Further disease progression was documented at month 17. He 
continued to receive TTFields treatment and bevacizumab until month 20, when he died. His 
adherence rate to TTFields therapy was 75.9%. 
Patient No. 6, a male in his 50s, was diagnosed with left frontal lobe GBM. He underwent 
GTR and received radiation and temozolomide and completed 6 cycles of high-dose mainte-
nance temozolomide, which was stopped due to disease progression on MRI. His tumor was 
MGMT negative, EGFR amplification positive, PTEN negative, and IDH1/2 negative. The pa-
tient had disease recurrence diagnosed at month 9. Bevacizumab was administered from 
months 10 to 13 before disease progression was noted. TTFields therapy was initiated at 
month 14, and disease progression was detected at month 17. TTFields therapy was stopped 
at month 18; his adherence rate was 48.2%. The patient was rechallenged with a single dose 
of bevacizumab shortly prior to stopping TTFields, and died at month 15. 
Patient No. 7, a male in his 40s, was diagnosed with left parietal lobe GBM. MGMT status 
was not run due to an insufficient specimen quantity. He underwent GTR followed by con-
comitant radiation therapy and temozolomide as well as 10 cycles of high-dose te-
mozolomide until disease progression on MRI. At month 13, the patient had disease progres-
sion and he was treated with bevacizumab in a clinical trial from months 14 to 24, when 



















   
   
   
   
   
   
   
   
   
   























Case Rep Neurol 2016;8:1–9 
DOI: 10.1159/000442196 
 
© 2016 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/crn 
Ansstas and Tran: Treatment with Tumor-Treating Fields Therapy and Pulse Dose 




tinued until month 35, when it was stopped due to disease progression and a decline in the 
patient’s performance status; his adherence rate was 73.2%. Further disease progression 
was documented at month 26, and the patient was rechallenged with bevacizumab from this 
date until month 36. The patient died at month 38. 
Patient No. 8, a female in her 60s, was diagnosed with left frontal lobe GBM on Decem-
ber 16, 2011, and underwent GTR followed by concomitant radiation therapy and te-
mozolomide. Her tumor was MGMT negative, EGFR amplification positive, IDH1 negative, 
and 1p,19q co-deletion negative. She received 6 cycles of high-dose maintenance te-
mozolomide, which was stopped due to disease progression on MRI. She was treated with 
bevacizumab in a clinical trial. Disease recurrence was detected at month 10, and she re-
ceived bevacizumab from months 10 until 19. TTFields therapy was initiated at month 16 
and stopped at month 21; her adherence rate was 85.3%. The patient died at month 22. At 
her last MRI at month 20, she had no disease progression. 
Results 
Our 8 patients had a median OS of 216 days (7.2 months) from first day of treatment 
with TTFields therapy. Median OS from last dose of bevacizumab was 237 days (7.9 months; 
table 2). Median OS from first dose of bevacizumab rechallenge was 172 days (5.7 months). 
Median time on bevacizumab prior to treatment with TTFields therapy was 236.5 days 
(7.9 months). Median time on TTFields therapy was 155 days (5.2 months), and median time 
from start of TTFields therapy to radiographic progression was 80.5 days (2.7 months). 
In 3 of the 5 patients rechallenged with bevacizumab, TTFields therapy was adminis-
tered concurrently for up to 9 months, then discontinued prior to bevacizumab. One patient 
received only a single dose of bevacizumab and 1 patient continued on both TTFields thera-
py and bevacizumab once bevacizumab was initiated. 
Mean patient adherence rate to TTFields therapy was 74.2% (range, 48.2–92.9%), with 
adherence defined as wearing the device at least 18 h per day. Patients highly adherent to 
treatment – who were also those who received pulse dose bevacizumab – had the longest OS, 
consistent with prior data. Patient No. 4 had an adherence rate of 92.9%; her time from first 
day of TTFields therapy to death was 276 days (9.2 months) and, from first dose of beva-
cizumab rechallenge until death, 150 days (5.0 months). Patient No. 7, with an adherence 
rate of 73.2%, had a time from first day of TTFields therapy to death of 406 days (13.5 
months) and, from first dose of bevacizumab rechallenge until death, 349 days (11.6 months; 
see fig. 1). 
Discussion 
This set of cases describes a heavily pretreated population with bevacizumab-refractory 
recurrent GBM with minimal therapeutic options. Following disease progression on bevaci-
zumab, TTFields therapy alone was administered, stabilizing these patients and allowing 
them to be rechallenged with bevacizumab once they became symptomatic. 
Our 8 patients had a median OS of 7.9 months following progression on bevacizumab 
and treatment with TTFields. These results compare favorably to what has been observed in 
other studies for the same population of bevacizumab-refractory GBM. In a retrospective 
study, patients who presented with bevacizumab-refractory recurrent GBM had a median OS 
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days (1.1 months), in contrast to a median OS of 149 days (5.0 months) for the 3 patients 
restarted on bevacizumab [10]. Our results in the 5 patients who were rechallenged with 
bevacizumab show a similar prolonged OS, a median of 172 days (5.7 months) from the time 
of bevacizumab rechallenge. In contrast, the 3 patients who were not rechallenged with 
bevacizumab had a median survival of 11 days. 
TTFields therapy is well tolerated with a favorable safety profile [13], and patients in 
the phase 3 trial reported improved quality of life compared with patients receiving chemo-
therapy [3]. As a local treatment, the most commonly observed toxicity with TTFields thera-
py is skin irritation from the transducer arrays [3, 13]. In the phase 3 trial of TTFields thera-
py in recurrent GBM, higher adherence was found to correspond with greater survival bene-
fit, as did age ≤60 years [11], both of which we found in this case series. 
In this case series, we describe 8 patients with recurrent GBM for whom it was safe to 
stop treatment with bevacizumab – despite the concern of possible rapid disease progres-
sion upon bevacizumab withdrawal –, effectively use TTFields therapy, and then rechallenge 
with bevacizumab once they became symptomatic and/or had evidence of radiographic pro-
gression. This ‘pulse dose’ approach to bevacizumab administration, combined with 
TTFields therapy, has not previously been described in this population, and its efficacy will 
need to be investigated further in a prospective clinical study. In the meantime, the results 
from this limited series suggest that this approach is well tolerated and may be considered 
an option in these very refractory patients. 
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Table 1. Patient baseline demographics and characteristics 
 
 
 Patient No. 
  1 2 3 4 5 6 7 8 
         
         
Gender Male Male Female Female Male Male Male Female 
                  Age at diagnosis, 
years 
49 48 52 60 35 51 48 62 
                  GBM de novo Yes Yes No1 Yes No2 Yes Yes Yes 
                                Molecular testing 
MGMT Negative Negative  Positive Negative Negative Insufficient  
specimen 
Negative 
IDH1 and/or IDH2 Negative – Positive – Positive Negative – Negative 
EGFR amplification – – Negative – Negative Positive – Positive 
1p,19q  
co-deletion 
– – Negative – Negative – – Negative 
Other – – Loss of 10q 
negative 





                  Tumor  
location 










Left frontal  
lobe 
Left parietal  
lobe 
Left frontal  
lobe 
                  Resection Near GTR GTR Near GTR Partial GTR GTR GTR GTR 
                  XRT Yes Yes Yes 63 Gy None due to  
previous XRT for  
low-grade glioma 
60 Gy 63 Gy 60 Gy 
                    Concurrent 
temozolomide 
(75 mg/m2/day) 
Yes Yes Yes Yes Yes Yes Yes Yes 
 
 
1 Prior low-grade glioma in the 1980s. 2 Prior low-grade glioma in 2007. GTR = Gross total resection; TMZ = temozolomide; NCCTG = North 
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Table 2. Duration of bevacizumab and TTFields therapy (TTF) and OS by patient 
 
 
Treatment duration Patient No. 
  1 2 3 4 5 6 7 8 
         
         
Initial duration of bevacizumab treatment, days 154 182 221 315 276 91 322 252 
TTF for recurrence on trial No Yes1 No No No No No No 
TTF line of therapy Third Third Third Third Fourth Third Third Third 
Duration on TTF, days 80 60 157 252 235 154 321 153 
Time on TTF until radiographic progression, days 112 55 N/A2 124 55 105 56 153 
TTF adherence, % N/A3 60.2 84.0 92.9 75.9 48.2 73.2 85.3 
Time from first day of TTF to death, days 211 614 221 276 253 169 406 165 
Time from last dose of first round of bevacizumab to death, days 246 103 228 304 295 182 411 185 
                  Patients rechallenged with bevacizumab         
Time from first dose until death, days N/A5 N/A4 172 150 197 366 349 N/A7 
Survival from diagnosis until death, days – – 510 810 604 569 1,133 – 
Patients not rechallenged with bevacizumab         
Time from survival from last day of TTF until death, days 131 1 – – – – – 11 
Survival from diagnosis until death, days 837 461 – – – – – 661 
         
         
1 Novocure and genomic analysis study. 2 No progression documented on MRI; bevacizumab initiated for functional decline. 3 Patient lost to 
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Fig. 1. Radiographic appearance of bevacizumab-refractory GBM treated with TTFields and subsequently 
rechallenged with bevacizumab. Representative pictures of serial gadolinium contrast-enhanced brain 
MRI scans of patients No. 4 and No. 7 are shown. Colored bars denote time line of TTFields therapy and 
bevacizumab rechallenge. The time frame is in months, starting from the first documented radiographic 
diagnosis of bevacizumab-refractory GBM. Patient No. 4 demonstrated an initial response to TTFields at 2 
months but progressed radiographically at 4 months. Upon rechallenge with bevacizumab, this patient’s 
GBM demonstrated a radiographic response to bevacizumab again. Patient No. 7 did not demonstrate 
radiographic response to TTFields in the first 2 months. However, this patient had a durable radiographic 
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